✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE3
Participants
ALL
Age Range
18 Years+
About This Trial
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on:
* Percent change in body weight
* Change in hemoglobin A1c (HbA1c)
Who Can Join?
Key Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus (T2DM). * Receiving stable therapy for T2DM for 3 months prior to Screening. This includes diet and/or exercise alone or in combination with any oral medication for T2DM treatment except for DPP-4 inhibitors. Participants can be treatment naΓ―ve if they have an HbA1c of 6.5% to 7.5%, inclusive. * BMI β₯27 kg/m^2. * History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months. Key Exclusion Criteria: * Current diagnosis or history of type 1 diabetes mellitus (T1DM) or any other type of diabetes except T2DM. * History of diabetic ketoacidosis or hyperosmolar state/coma within 1 year prior to Screening. * History of severe hypoglycemia or hypoglycemia unawareness within 1 year prior to Screening. * Started medications within 3 months prior to Screening that may cause significant weight change,…
⚠ Always speak to your doctor before applying to any clinical trial.
More Diabetes & Weight Trials
Recruiting
Safety and Effectiveness of Orbera365β’ Intragastric Balloon System
Recruiting PHASE3A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in…
Recruiting PHASE1A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult…